Zinc differentially modulates DNA damage induced by anthracyclines in normal and cancer cells

Experimental Oncology

Volumn 34, Issue 4, 2012, Pages 327-331

  Wysokinski, D ^a   Blasiak, J ^a   Wozniak, K ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

Acute lymphocytic leukemia; DNA damage; Doxorubicin; Idarubicin; Zinc

Indexed keywords

DOXORUBICIN; IDARUBICIN; ZINC;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG POTENTIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOCYTE;

ADULT; ANTHRACYCLINES; CELL LINE, TUMOR; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; DOXORUBICIN; HUMANS; IDARUBICIN; LYMPHOCYTES; ZINC;

EID: 84872400590     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Maret W, Sandstead HH. Zinc requirements and the risks and benefits of zinc supplementation. J Trace Elem Med Biol 2006; 20: 3-18.
2. Murakami M, Hirano T. Intracellular zinc homeostasis and zinc signaling. Cancer Sci 2008; 99: 1515-22.
3. Butler JS, Loh SN. Zn(2+)-dependent miss folding of the p53 DNA binding domain. Biochemistry 2007; 46: 2630-9. (Pubitemid 46420239)
4. Maret W. Metallothionein redox biology in the cytoprotective and cytotoxic functions of zinc. Exp Gerontol 2008; 43: 363-9. (Pubitemid 351522406)
5. Ho E. Zinc deficiency, DNA damage and cancer risk. J Nutr Biochem 2004; 15: 572-8. (Pubitemid 39470210)
6. Song Y, Leonard SW, Traber MG, et al. Zinc deficiency affects DNA damage, oxidative stress, antioxidant defenses, and DNA repair in rats. J Nutr 2009; 139: 1626-31.
7. Kunzmann A, Dedoussis G, Jajte J, et al. Effect of zinc on cellular poly(ADP-ribosyl)ation capacity. Exp Gerontol 2008; 43: 409-14. (Pubitemid 351522404)
8. Cabreiro F, Perichon M, Jajte J, et al. Zinc supplementation in the elderly subjects: effect on oxidized protein degradation and repair systems in peripheral blood lymphocytes. Exp Gerontol 2008; 43: 483-7. (Pubitemid 351540837)
9. Eby GA. Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation - a case history and hypothesis. Med Hypothesis 2005; 64: 1124-6.
10. Czyzewska MW. Immunostimulatory effect of zinc in patients with acute lymphoblastic leukemia. Folia Heamatol 1978; 105: 727-32.
11. Hortobagyi GN. Anthracyclines in the treatment of cancer. An overview. Drugs 1997; 4: 1-7. (Pubitemid 27487789)
12. Cozzi P, Mongelli N, Suarato A. Recent anticancer cytotoxic agents. Curr Med Chem Anticancer Agents 2004; 4: 93-121. (Pubitemid 38404687)
13. Ramirez LY, Huestis SE, Yap TY, et al. Potential chemotherapy side effects: what do oncologists tell parents? Pediatr Blood Cancer 2009; 52: 497-502.
14. Simunek T, Sterba M, Popelova O, et al. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009; 61: 154-71.
15. Menna P, Gonzalez Paz O, Chello M, et al. Anthracycline cardiotoxicity. Expert Opin Drug Saf 2012; 11: S21-36.
16. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol 2005; 131: 561-78. (Pubitemid 43899624)
17. Blasiak J, Gloc E, Wozniak K, et al. Genotoxicity of idarubicin and its modulation by vitamins C and E and amifostine. Chem Biol Interact 2002; 140: 1-18. (Pubitemid 34606848)
18. Jantas D, Lason W. Protective effect of memantine against doxorubicin toxicity in primary neuronal cell cultures: influence a development stage. Neurotox Res 2009; 15: 24-37.
19. Cullinane C, Cutts SM, Panousis C, et al. Interstrand cross-linking by adriamycin in nuclear and mitochondrial DNA of MCF-7 cells. Nucl Acids Res 2000; 28: 1019-25. (Pubitemid 30085330)
20. Wilstermann AM, Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Curr Top Med Chem 2003; 3: 321-38.
21. Cutts SM, Nudelman A, Rephaell A, et al. The power and potential of doxorubicin-DNA adducts. IUBMB Life 2005; 57: 73-81. (Pubitemid 40632297)
22. Singh NP, McCoy T, Tice RR, et al. A simple technique for quantification of low levels of DNA damage in individual cells. Exp Cell Res 1988; 175: 184-92.
23. Blasiak J, Kowalik J. A comparison of the in vitro genotoxicity of tri- and hexavalent chromium. Mutat Res 2000; 469: 135-45. (Pubitemid 30628682)
24. Tice RR, Agurell E, Anderson D, et al. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ Mol Mutagen 2000; 35: 206-21. (Pubitemid 30196665)
25. Lehmann M, Vilar KSP, Franco A, et al. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila somatic mutation and recombination test. Environ Mol Mutagen 2004; 43: 250-7. (Pubitemid 38702631)
26. Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Res 2009; 37: 738-48.
27. Yokochi T, Robertson KD. Doxorubicin inhibits DNMT1 resulting in conditional apoptosis. Mol Pharmacol 2004; 66: 1415-20. (Pubitemid 39564768)
28. Celik H, Arinc E. Bioreduction of idarubicin and formation of ROS responsible for DNA cleavage by NADPH-cytochrome P450 reductase and its potential role in the antitumor effect. J Pharm Pharmaceut Sci 2008; 11: 68-82.
29. Sliwinski T, Czechowska A, Kolodziejczak M, et al. Zinc salts differentially modulate DNA damage in normal and cancer cells. Cell Biol Int 2009; 33: 542-7.
30. Maret W, Krezel A. Cellular zinc and redox buffering capacity of metallothionein/thionein in health and disease. Mol Med 2007; 13: 371-5. (Pubitemid 47378138)
31. Franklin RB, Costello LC. The important role of the apoptotic effects of zinc in the development of cancers. J Cell Biochem 2009; 106: 750-7.